The compounds included are Albiglutide, Avexitide, Dulaglutide, Exenatide, Glucagon, Liraglutide, Lixisenatide, Pramlintide, Semaglutide, and Tirzepatide, which collectively represent a broad spectrum of incretin mimetics and peptide-based agents with clinical relevance in metabolic disorders such as type 2 diabetes and obesity. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.